retatrutide 2 months Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide—A Game Changer in Obesity

The medication masked the symptoms without correcting the hormonal environment

Some users respond quickly while others need the full escalation period before seeing meaningful changes

Initial information indicates a majority of the weight loss occurs within the first 24 weeks, demonstrating a rapid time to onset

Head-to-head trials against semaglutide are recruiting and have not been reported

Understanding why plateaus occurfrom metabolic adaptation and hormonal changes to behavioural factorsis essential for overcoming them

Berberine shows modest evidence of supporting GLP-1 secretion and weight management, but it acts differently than GLP-1 medications, carries risks, including drug interactions, and should only be taken under the guidance of a licensed healthcare provider